Introduction
episode of variceal bleeding should be effectively prevented. In the past 2 decades, shunt operation and sclerotherapy have been tried with variable success. However, the resultant morbidities and mortalities have led to both modalities being abandoned. 1, 2 On the other hand, endoscopic variceal ligation (EVL) has been well documented to be an effective method in the prevention of first variceal bleeding with a relatively low risk. [3] [4] [5] A meta-analysis showed that EVL was superior to β-blocker in reducing the occurrence of first variceal bleeding. 4 A combination of β-blocker and isosorbide-5-mononitrate (ISMN) has proven to be more effective than β-blocker alone in the prevention of secondary variceal bleeding. 6 Although combined treatment with nonselective β-blockers and nitrate has also been shown to be effective against first variceal bleeding, 7 to our knowledge, the comparison between EVL and combined drug therapy in the prevention of first variceal bleeding has never been reported. We, therefore, aimed to compare the efficacy and safety of band ligation with drug treatment using nadolol plus ISMN for the prophylactic prevention of first bleeding in cirrhotic patients with high-risk esophageal varices.
Methods

Patients
Between October 2002 and December 2004, patients presenting with chronic liver disease and esophageal varices were considered for enrollment in the trial. Inclusion criteria were: (1) portal hypertension caused by cirrhosis; (2) esophageal varices of moderate or severe grade, associated with any red color signs (red wale marking, cherry red spots, hematocystic spots); (3) no history of hemorrhage from esophageal varices; (4) no current treatment with β-blockers or nitrates. The diagnosis of cirrhosis was based on liver biopsy or clinical examination, biochemical tests and imaging studies. Exclusion criteria were: (1) age > 75 years or < 20 years; (2) presence of malignancy, uremia or other serious medical illness that could reduce life expectancy; (3) refractory ascites, hepatic encephalopathy or marked jaundice (serum bilirubin > 10 mg/dL); (4) history of shunt operation, transjugular intrahepatic portosystemic stent shunt or endoscopic therapy (sclerotherapy or EVL); (5) contraindications to β-blockers or nitrates, e.g. asthma, chronic obstructive airway disease, diabetes mellitus with documented hypoglycemic episodes, congestive heart failure, peripheral vascular disease, hypotension (systolic blood pressure < 90 mmHg) and bradycardia (pulse rate < 60 beats/minute); (6) allergy to either trial medication or inability to cooperate.
Randomization
Patients eligible for the trial were randomized to undergo band ligation (EVL group) or treatment with nadolol plus ISMN (combination group). Randomization was by means of opaque, sealed envelopes numbered according to a table of random numbers. All the patients signed an informed consent and were followedup regularly. The study protocol was approved by the ethics committee of our hospital.
Assessment
The diagnosis of cirrhosis was based on clinical and/ or imaging findings. The severity of liver disease was assessed at presentation (Pugh modification of the Child classification). 8 Assessment of variceal size (degree) was based on the classification of Beppu et al. 9 Patients in both groups were advised to abstain from drinking alcohol.
Band ligation, nadolol and ISMN
Band ligation was applied after premedication with hyoscrine-N-butyl bromide (20 mg intramuscularly). A multiband ligator (Saeed Four-Shooter; WilsonCook Medical Inc., Winston-Salem, NC, USA) and a videoendoscope (XQ 230; Olympus Optical Co., Ltd., Tokyo, Japan) were utilized. Ligations were performed by 2 experienced endoscopists. During each session of treatment, 3-4 elastic bands were placed to ligate varices. The treatment interval was 4 weeks until all varices were obliterated or the residual varices were too small to be ligated. After variceal obliteration, patients in the EVL group underwent endoscopy every 3 months. EVL was repeated if varices recurred.
Among the patients in the combination group, 40 mg of nadolol once daily (E.R. Squibb & Sons, Inc., Princeton, NJ, USA) was given initially and then adjusted according to the dosage that reduced resting pulse rate by up to 25% or 55 beats/minute. Subsequently, 20 mg oral ISMN (F. Hoffmann-La Roche Ltd., Milan, Segrate, Italy) once per day was administered concomitantly. The dose was increased over a period of 1 week to 20 mg bid if tolerable. Compliance was assessed by reduction of pulse rate and/or by quantifying the number of tablets consumed, and inquiring about how often patients did not take the drugs. In case of side effects, nadolol was continued in patients who could not tolerate ISMN, and ISMN was continued in patients whose side effects were nadolol-related.
Patients in both groups were advised to undergo follow-up abdominal ultrasonography and to have serum α-fetoprotein and biochemical tests of liver function at 3-month intervals.
Variceal bleeding and management
Patients suspected to have upper gastrointestinal bleeding underwent endoscopy within 12 hours of presentation. For patients with suspected esophageal variceal bleeding, supportive measures included blood transfusion, infusion of vasoconstrictor agents and administration of lactulose and prophylactic antibiotics. Esophageal variceal bleeding was defined as the appearance of hematemesis or melena, documentation of esophageal variceal bleeding at endoscopy, and a requirement for transfusion of > 2 units of blood to maintain stable vital signs. EVL was performed within 24 hours of esophageal variceal bleeding in both groups. Elective EVL for prevention of recurrent bleeding was employed for those patients with failure of prophylaxis, if possible. Ligation sessions were repeated every 3-4 weeks until the varices were obliterated for both treatment groups.
Statistical analysis
Data were expressed as mean ± standard deviation. Quantitative variables were compared with Student's t test, and qualitative variables with χ 2 test and Fisher's exact test when appropriate. Kaplan-Meier estimation was applied to examine the time to first occurrence of variceal bleeding and the time to death. In the analysis of bleeding, patients were censored at death or at the end of follow-up. In the analysis of survival, patients were censored only at the end of follow-up. Log rank test was used to examine the variation of bleeding episodes and survival rate. Cox regression analysis was used to detect possible prognostic variables other than treatment modality on bleeding and survival rates. All hypothesis tests were conducted against a 2-sided alternative, where appropriate. A p value < 0.05 was considered to be significant. Analyses were performed using SPSS (SPSS Inc., Chicago, IL, USA). The possibility of hemorrhage from esophageal varices after prophylactic banding ligation varies from 0% to 15%. 10 The possibility of esophageal variceal bleeding after treatment with nadolol plus ISMN is about 12%. 6 We anticipated that if the possibility of first bleeding from esophageal varices was 12% in those receiving nadolol plus ISMN, which could be reduced to 6% in patients treated with EVL, with a 2-tailed test to achieve a statistical power of 80% and type I error of 5%, a sample size of 352 patients in each group would be required. However, it is impossible to enroll so many patients in a single center. Preliminary analysis of our results showed a similar trend. Thus, after 2 years of enrollment, we decided to terminate this study.
Results
General characteristics
During the study period, 70 patients were screened for possible inclusion in the trial. Of the 70 eligible patients, 9 were excluded due to hepatocellular carcinoma (2 patients), uremia (1), deep jaundice (2), refractory ascites (2), asthma (1) and hypotension (1) .
A total of 61 patients were ultimately recruited: 30 were randomized to the EVL group and 31 to the combination treatment group with nadolol plus ISMN. The result was based on per protocol analysis (Figure 1 ). The 2 groups were comparable with regard to age, gender, variceal size and severity of liver disease (Table 1) . There were no significant differences in both groups. The median duration of follow-up was 22.8 months (range, 4.6-41.7 months) for the EVL group and 23.8 months (range, 3.9-39.6 months) for the combination group. Three patients in the EVL group and 2 in the combination group continued to drink alcohol. No patients in either group were lost to follow-up.
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Assessed for eligibility (Included) (n = 70)
Lost to follow-up (n = 0) Analysis (n = 30) Analysis (n = 31) Figure 1 . Clinical flow diagram of 77 cirrhotic patients assessed for eligibility. A total of 16 patients were excluded due to hepatocellular carcinoma, uremia, deep jaundice, refractory ascites, asthma and hypotension. A total of 61 patients were ultimately recruited, of which 30 were randomized to the EVL group and 31 to the combination group. No patients in either group were lost to follow-up. Therefore, all 61 patients were included in the analysis. EVL = endoscopic variceal ligation.
Variceal obliteration was achieved in 24 patients (80%) in the EVL group. The mean number of treatment sessions required for successful obliteration was 3.2 ± 0.9. The causes of failure to achieve variceal obliteration included noncompliance (5 patients) and hepatic failure (1 patient). In the combination group, the median daily doses of nadolol and ISMN administered were 40 mg and 20 mg, respectively.
There were 10 patients each in both treatment groups with initial presence of gastric varices on enrollment. Newly developed gastric varices were observed in 2 patients (7%) in the EVL group but none in the combination group. 
Upper gastrointestinal hemorrhage
Complications
No serious adverse effect was found in either group. Minor complications were noted in 5 patients (17%) in the ligation group and 3 (10%) in the combination group (p = 0.47). In the EVL group, 3 patients (10%) experienced transient dysphagia, 1 (3%) suffered from severe retrosternal pain that required pain control with analgesics and 1 (3%) developed esophageal ulcer after EVL. In the combination group, 2 patients complained of headache and 1 developed hypotension.
Mortality rates
There were 8 deaths in the EVL group and 6 deaths in the combination group (p = 0.49; Figure 3 ). One patient in the EVL group and 3 in the combination group died of uncontrollable variceal bleeding (Table 3) . Univariate analysis revealed that serum albumin, serum bilirubin, prothrombin time and presence of ascites were prognostic predictors of mortality, whereas multivariate analysis showed that prothrombin time was the only significant prognostic predictor of mortality (risk ratio, 1.69; 95% CI, 1.27, 2.23; p < 0.001) ( Table 4) . 
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Discussion
Variceal bleeding is a dreadful complication of portal hypertension, which carries a high mortality rate. 1 It is one of those complications that, if prevented, can lead to improved survival. An analysis comparing propranolol with endoscopic injection sclerotherapy and shunt surgery suggested that β-blocker was the only cost-effective modality for primary prophylaxis. 11 However, treatment with β-blocker does not result in obliteration of esophageal varices. Consequently, lifetime daily consumption of a β-blocker is necessary to maintain the effect. 12 Furthermore, the rate of non-response may be as high as 30%. 13 A significant number of patients (45%) reported side effects with β-blocker treatment, resulting in withdrawal from treatment in 30% of patients. 13 When propranolol is withdrawn, the risk of variceal hemorrhage returns to what would be expected in an untreated population. One study also reported that some patients might present with rebound bleeding upon abrupt cessation of treatment with β-blocker.
14 All of these situations are drawbacks of prophylactic β-blocker therapy against a first episode of variceal bleeding.
Because of an increase in mortality resulting from hepatic failure, nitrate monotherapy is not regarded as a useful regimen to prevent first variceal bleeding, despite a similar effectiveness to β-blocker monotherapy. 15 It has been demonstrated that combination therapy with a β-blocker and a nitrate could further reduce hepatic venous pressure and decrease the risk of primary variceal bleeding. Garcia-Pangan et al documented that hepatic venous pressure gradient (HVPG) decreased by more than 20% of baseline value in only 10% of patients receiving propranolol, but in 50% of patients receiving combined therapy. 16 Thus, from a clinical viewpoint, the efficacy and safety of a combination of β-blockers plus ISMN for primary prophylaxis is still controversial, 6, 17, 18 contrary to the secondary prophylaxis setting in which ISMN enhances the efficacy of a β-blocker. 19 A possible explanation for these results may depend on 2 facts: (1) most cirrhotic patients without episodes of variceal bleeding respond to β-blockers; 20 (2) the addition of ISMN reduces HVPG in non-responders to β-blocker, but not in responders. 21 However, the combination of β-blockers and ISMN has never been tried in primary prophylaxis in Chinese patients.
It is well accepted that EVL offers the same efficacy on varices as does endoscopic injection sclerotherapy but with fewer adverse effects and, thus, is the more favored endoscopic approach to prevent first variceal bleeding compared with sclerotherapy. 22 A metaanalysis of EVL for primary prophylaxis of esophageal variceal bleeding demonstrated that EVL achieved a lower risk for first variceal bleeding when compared with β-blocker (relative risk, 0.48). 4 Up to now, a large number of studies have investigated the roles of sclerotherapy, β-blocker and EVL in preventing first variceal bleeding. 2, 6 However, there is still no controlled study to compare EVL with a combination of nitrate plus β-blocker for prevention of first variceal bleeding. Hence, we carried out this study to investigate whether nadolol plus ISMN compared to EVL made a difference in the prevention of first variceal bleeding in patients with cirrhosis.
The present trial compared EVL with nadolol plus ISMN for prevention of first variceal bleeding. The upper gastrointestinal bleeding rate was 17% in the EVL group and 26% in the combination group (p = 0.53), a difference that was not statistically significant. Our esophageal variceal bleeding rate was 10% in the EVL group and 19% in the combination group (p = 0.47). Our results were comparable with those of previous trials that found variceal bleeding rates of 9% to 19% in patients receiving prophylactic EVL, 8, 9, [23] [24] [25] but slightly higher than the bleeding rate of 7.5% in patients treated with nadolol plus ISMN. 10 Because of the small difference in reducing variceal bleeding rate, it would require a large sample size to reach a statistically significant difference between EVL and combination drug therapy. EVL treatment intervals were 4 weeks instead of weekly. Thus, the length of time required to obliterate esophageal varices was slightly longer in the present trial. The current trial had fewer esophageal ulcers as compared with prior studies. This is in disagreement with a past study by Sarin et al, 24 which reported that esophageal ulcers were observed in 80% of patients. On the other hand, the current trial included cirrhotic patients with gastric varices. Only 1 patient in the combination group bled from gastric varices. To our knowledge, the presence of gastric varices is not an absolute contraindication to EVL. Therefore, cirrhotic patients with esophageal varix with/without gastric varix were analyzed for this study.
In combined medical therapy, the daily doses of nadolol and ISMN to prevent first esophageal variceal bleeding were lower in our patients compared to other trials. Borroni et al reported that their final daily dose of nadolol was 68 ± 7 mg and ISMN was given at the initial dose of 20 mg and doubled every 3-4 days until 40 mg bid. 26 A Spanish study used a mean dose of 95 ± 56 mg/day for nadolol and the dose of ISMN was increased to 40 mg bid. 27 We presume that the varying tolerable dose of ISMN among the different study groups may be ascribed to ethnic differences.
Incidences of aspiration pneumonia and esophageal bleeding after prophylactic EVL have been reported. 3 Fortunately, no serious complication was found in the current trial. Minor complications occurred with similar frequency in both groups.
There were no significant differences between the 2 treatment groups with regard to survival rates. Patients who underwent EVL had a lower risk of dying from uncontrollable variceal bleeding than those who received combination therapy, but the difference was not significant. Our study results are in agreement with those of a meta-analysis of primary prophylaxis, which showed that survival was similar between those treated with EVL and those treated with drug therapy. 4, 10 Our preliminary results suggest that EVL has similar effectiveness and safety to the combination of nadolol plus ISMN in the prophylaxis against first variceal bleeding. However, a larger, randomized controlled trial is needed.
